Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec 10;4(4):133.
doi: 10.3390/jof4040133.

Pre-Existing Liver Disease and Toxicity of Antifungals

Affiliations
Review

Pre-Existing Liver Disease and Toxicity of Antifungals

Nikolaos Spernovasilis et al. J Fungi (Basel). .

Abstract

Pre-existing liver disease in patients with invasive fungal infections further complicates their management. Altered pharmacokinetics and tolerance issues of antifungal drugs are important concerns. Adjustment of the dosage of antifungal agents in these cases can be challenging given that current evidence to guide decision-making is limited. This comprehensive review aims to evaluate the existing evidence related to antifungal treatment in individuals with liver dysfunction. This article also provides suggestions for dosage adjustment of antifungal drugs in patients with varying degrees of hepatic impairment, after accounting for established or emerging pharmacokinetic⁻pharmacodynamic relationships with regard to antifungal drug efficacy in vivo.

Keywords: antifungal agent; antifungal drug; hepatic impairment; invasive fungal infection; liver disease; toxicity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Limper A.H., Adenis A., Le T., Harrison T.S. Fungal infections in HIV/AIDS. Lancet Infect. Dis. 2017;17:e334–e343. doi: 10.1016/S1473-3099(17)30303-1. - DOI - PubMed
    1. Colombo A.L., de Almeida Júnior J.N., Slavin M.A., Chen S.C.A., Sorrell T.C. Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. Lancet Infect. Dis. 2017;17:e344–e356. doi: 10.1016/S1473-3099(17)30304-3. - DOI - PubMed
    1. Kontoyiannis D.P. Invasive mycoses: Strategies for effective management. Am. J. Med. 2012;125:S25–S38. doi: 10.1016/j.amjmed.2011.10.009. - DOI - PubMed
    1. Rodighiero V. Effects of liver disease on pharmacokinetics. An update. Clin. Pharmacokinet. 1999;37:399–431. doi: 10.2165/00003088-199937050-00004. - DOI - PubMed
    1. Gupta N.K., Lewis J.H. Review article: The use of potentially hepatotoxic drugs in patients with liver disease. Aliment. Pharmacol. Ther. 2008;28:1021–1041. doi: 10.1111/j.1365-2036.2008.03822.x. - DOI - PubMed

LinkOut - more resources